Medically reviewed by Susan Bard, MD Alopecia areata is a common hair loss condition. It affects people of all ages, races, ...

While similarities exist between types of alopecia, distinct clinical characteristics help patients & physicians ...

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

Bald spots can feel like a punch to your confidence - sudden, unexplained patches of missing hair are never welcome surprises ...

has granted Fast Track designation to bempikibart for the treatment of Alopecia Areata (AA), an autoimmune disease that attacks hair follicles causing patchy hair loss. Fast Track is a process ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other ...

Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program.